Neuberger Berman Group
ADVM

Neuberger Berman Group’s Adverum Biotechnologies ADVM Stock Holding History

Neuberger Berman Group’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,020
Closed -$550K – 1596
2014
Q4 		$550K Buy
+1,020
New +$393K ﹤0.01% 1332

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Neuberger Berman Group's ADVM Position: Q1 2015 in Review

Neuberger Berman Group sold out of Adverum Biotechnologies (ADVM) in Q1 2015, closing a stake of 1,020 shares — an estimated $550K sold.

Neuberger Berman Group first reported a position in ADVM in Q4 2014 and held it in 1 quarter. The position peaked at $550K in Q4 2014. 113 funds tracked by Wall St. Rank hold ADVM as of Q1 2015.

  • Neuberger Berman Group reported no remaining Adverum Biotechnologies position as of Q1 2015 after selling out during the quarter.
  • Neuberger Berman Group sold 1,020 Adverum Biotechnologies shares in Q1 2015, an estimated $550K.
  • Neuberger Berman Group first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 1 quarter.
  • Neuberger Berman Group's Adverum Biotechnologies position peaked at $550K in Q4 2014.
  • 113 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2015.

Based on Neuberger Berman Group's 13F filing for Q1 2015, filed 6 May 2015.